NPAS2 and lung adenocarcinoma: In this regard, NPAS2 was identified as a component of a four-chromatin-regulator hub (CBX7, HMGA2, NPAS2 and PRC1) allowing risk stratification and outcome prediction in lung adenocarcinoma patients.